PRDX1-KD in AML cells significantly reduced their IC50 for ADR, indicating that PRDX1 depletion sensitized the AML cells to the conventional chemotherapeutic drug (Fig. 6B). The gene discussed is PRDX1; the disease is acute myeloid leukemia.